Trametinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), G-BA (Germany) and NICE (England), among others, recommended or restricted trametinib, while AWMSG (Wales) did not recommend it.
On the same population the two systems disagree outright: SMC (Scotland) recorded restricted for “In combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.”, while AWMSG (Wales) recorded not recommended for “For the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.”.
Assessment has run over 11.5 years, from 2014 at PBAC (Australia) to 18 Jan 2026 at NYE METODER (Norway).
TLV (Sweden) changed its position: restricted on 22 Jun 2016, recommended by 25 Mar 2019.
No assessment is on file from HAS (France), PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
The file is active: 4 of 18 records date from 2023 or later.
5 distinct indication wordings are recorded for trametinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 18 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess trametinib, in 2014; NYE METODER (Norway) did not open a file until 18 Jan 2026 — an unusually long tail of 11.5 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 8 years in total.
6 of the 8 agencies here assessed trametinib more than once, G-BA (Germany) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for trametinib.
The full ledger for trametinib reads 12 recommended, 3 restricted, 1 no benefit and 1 deferred to NICE, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 17 Oct 2024 | Spexotras — benefit assessment §35a | added benefit: considerable (hint) | source |
| AIFA (Italy) | 16 Oct 2024 | "Glioma ad alto grado (HGG): trametinib in associazione con dabrafenib è indicato per iltrattamento di pazienti pediatri… | innovative · reimbursed class H | source |
| SMC (Scotland) | 8 Mar 2021 | For treatment in combination with dabrafenib (Tafinlar) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. This is an… | accepted (restricted) | source |
| TLV (Sweden) | 25 Mar 2019 | Mekinist ingår i högkostnadsskyddet med generell subvention | general subsidy | source |
| PBAC (Australia) | 2016 | Melanoma | The PBAC recommended continuation of the Authority required listing of trametinib, for use… | source |
13 further decisions for trametinib, across 8 agencies, are not shown here. They include the most recent record on file, 18 Jan 2026 from NYE METODER (Norway); its outcome is in the subscriber dataset. They link to 10 further source documents.
Related molecules
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
- ribociclib — same ATC class L01E — Antineoplastics
Coverage: 18 decisions for trametinib from 8 agencies, 2014 to 2026. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.